volume 1, issue 3, P100174 2020
DOI: 10.1016/j.xpro.2020.100174
View full text
|
Sign up to set email alerts
|
Share

Abstract: Summary Glioblastoma (GBM) is the most common malignant adult brain tumor that is resistant to the standard care therapy. Advances in chimeric antigen receptor (CAR) T cell therapies have spurred renewed interest in developing CAR T cell therapies to target chemoradiotherapy-resistant brain tumor-initiating cells. This protocol shows how to isolate peripheral blood mononuclear cells from healthy donors and generate CAR T cells for the antigens of interest, and how to intracranially inject the CAR T …

Expand abstract